Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$15.08 USD
+0.20 (1.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Takeda Pharmaceutical Co. (TAK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.33 | $16.60 | $13.40 | 3.02% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Takeda Pharmaceutical Co. comes to $15.33. The forecasts range from a low of $13.40 to a high of $16.60. The average price target represents an increase of 3.02% from the last closing price of $14.88.
Analyst Price Targets (3 )
Broker Rating
Takeda Pharmaceutical Co. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TAK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | Cowen & Co. | Michael Nedelcovych | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $15.33 |
LT Growth Rate | 33.30% |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | NA |